DIABETES RESEARCH A CLINICIAN S OVERVIEW
|
|
- Justin Floyd
- 6 years ago
- Views:
Transcription
1 DIABETES RESEARCH A CLINICIAN S OVERVIEW Alan B. Cortez, MD Chief, Pediatrics Pediatric Endocrinology Kaiser-Permanente Orange County January 21, 2012
2 Research Overview Biotechnology Treatment Pharmaceutical Treatment Biological Treatment/Cure Biological Prevention Nutritional Management Complication Prevention/Management Epidemiology
3 Biotechnology Insulin pump Glucose sensor Improvements in accuracy, predictive capabilities, and comfort; better understanding of how to use it Augmented insulin pump current sensors may be better at detecting decreasing bgs than increasing bgs. (Ward et al 2011 Diab Med) Artificial Pancreas
4
5 Then. Now
6 Types of Artificial Pancreas Device Systems (APDS) CTR (Control to Range) Hypoglycemia Pump Shut off (Choudhary et al 2011) Hyperglycemia CTT (Control to Target) Insulin only vs Insulin/Glucagon Degree of Patient Control Pressing the mealtime button? Calibration with fingersticks Manual Override?
7 Full Closed Loop Vs. Hybrid Weinzimer et al. Diabetes Care May 2008 vol. 31 no
8 Distance Speed Acceleration Change in Accel Algorithm
9 Highlights from 64 Page FDA Guidelines- December 2011 Define types and subtypes of APDS Defines what data the FDA wants to see Delineates the 3 phase study approach- Early Feasibility, Transitional Clinical, Pivotal Clinical Define goals of rx- e.g., 0.4 reduction in A1c %, 30% reduction in hypoglycemia Define best populations to study- (e.g., doing well vs. not doing well; on pump/sensor vs. shots Proprietary Secrecy of Algorithms?
10 Pharmaceuticals- goals Safety- (don t cure the disease and kill the patient) Safety and Efficacy Maximized (Combinations of meds at lower doses that improve insulin secretion, enhance insulin action, increase glucose utilization, prevent glucose absorption, prevent complications, prevent/treat obesity) Prevention of islet cell apoptosis Islet Cell regeneration Physiologic and Convenient Insulin Delivery
11 Class of Diabetes Agents Sulfonylureas Biguanides Alpha-Glucosidase Inhibitors Thiazolidinediones Meglitinides DPP-4 Inhibitors GLP-1 Agonists Amylin Analogs Insulins/Insulin Analogs Combos/ Long Acting Preps Specific Agents glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Micronase) Metformin (Glucophage) Glyset (miglitol), Precose (acarbose) Actos (pioglitzone), Avandia (rosiglitazone) Prandin (repaglinide), Starlix (nateglinide) Januvia (sitagliptin), Tradjenta (linaglptin), Onglyza (saxagliptin), Galvus (vildagliptin) Byetta (exanatide), Victoza (liraglutide) Symlin (Pramlinitide) Fast- Novolog (aspart), Humalog (lispro), Apidra (glulisine); Intermediate- NPH; Slow- Lantus (glargine), Levemir (detemir) Too numerous to mention!
12 Pharmaceuticals New Type 2 Products Juvisync (Sitagliptin and simvastatin) SGLT2 inhibitors (increase renal loss of glucose) Glucokinase agonists (lower set point for insulin release) GPR40 agonists- (enhance insulin release) 11 beta hydroxysteroid inhibitor (decrease counterregulatory hormones) Glucagon receptor antagonist (decrease gluconeogenesis and glycogenolysis) Glycogen inhibitors (decrease stored glucose)
13 State of the Art? Motivated Patient 1 st med: Metformin (unless thin?) 2 nd med: Insulin Secretagogue (sulfonylurea, DPP- 4 inhibitor, GLP-1 agonist) 3 rd/4th med(s): Basal Insulin (debate:?1 st med) or consider adding other med classes 5 th med: Bolus insulin
14 Pharmaceuticals- Insulin Making Insulin Superfast Zincless insulin (Biodel- Viaject/Linjeta) Hyaluronidase (Halozyme) Glucose-Responsive Insulin New Basal Insulin (Lilly- LY and LY , Novo- 40-hour degludec) Inhaled Insulin- (Afrezza) Pfizer and Lilly out Mannkind in (bought Exubera factory)
15
16
17
18 Pharmaceuticals Making Insulin Superfast Zincless insulin (Biodel- Viaject/Linjeta) Hyaluronidase (Halozyme) Glucose-Responsive Insulin New Basal Insulin (Lilly- LY and LY , Novo- 40-hour degludec) Inhaled Insulin- (Afrezza) Pfizer and Lilly out Mannkind in (bought Exubera factory)
19 Glucose-Responsive Insulin- Smartinsulin Low Blood Glucose High Blood Glucose GRI GRI P B GRI L GRI H M Insulin Glucose
20 Pharmaceuticals Making Insulin Superfast Zincless insulin (Biodel- Viaject/Linjeta) Hyaluronidase (Halozyme) Glucose-Responsive Insulin New Basal Insulin (Lilly- LY and LY , Novo- 40-hour degludec) Inhaled Insulin- (Afrezza) Pfizer and Lilly out Mannkind in (bought Exubera factory)
21 New Inhaled Insulin is Smaller
22 Pharmaceuticals Obesity- last approval was Xenical in 1999 Cannabinoid-1 receptor blocker (rimonabant) Should be many candidate hormones to enhance or block the new hormones, but nothing so far. Phentermine/Topiramate (Qnexa) BuprorionSR/Naltrexone SR (Contrave)
23
24 Biological- Beta Cell Replacement Strategies Extracted vs. Created Cultured vs. Fresh Natural vs. Engineered Beta Cells vs. Islet Cells Human Cells vs. Animals Cells Living vs. Cadaveric Single donor vs. Multiple Encapsulation vs. Immunosuppression Portal vs. Peripheral Liver vs. Pancreas Safety vs. Unintended consequences Edmonton Protocol (2000)- 2-3 pancreata, islet cell purification process, portal vein injection, less severe immunosuppression. MAJOR STEP FORWARD
25 Islet Cell Microencapsulation
26 Islet Cell Macoencapsulation
27 Islet Cell Regeneration Growth Factors (not eating Lettuce!) Genetic Engineering In vivo vs. ex vivo vs. in vitro RIP3.1 promotor- beta cell regeneration in streptozotocin- treated rats Chen et al 2010 Beta Cell vs Islet Cell
28 Diabetes Dogs
29 Prevention of Diabetes- Type 2 Type 2- Still #1: diet, exercise, weight loss Emerging Role of Bariatric Surgery- e.g., 2011 IDF paper metformin, acarbose, Xenical
30 Prevention of Diabetes- Type 1 Trialnet and other studies Prevention of Insulitis (in both genetically at risk and in everyone) Prevention of Progression from Insulitis to Diabetes Prevention of Progression form Honeymoon Period to Complete Type 1 DIabetes
31 BETA CELL MASS Loss of Beta Cell Function and Intervention in Type 1 Diabetes Prevent any damage Maternal (DHA) TRIGR (formula) TEDDY (enviro) Vaccine (GAD) NCS (enviro) GENETIC PREDISPOSITION Prevent early damage INSULITIS to BETA CELL INJURY Progressive loss of insulin function over ~ 5 yrs Anti-CD3 Anti-CD-20 Prevent Anti- CTLA-4 further Oral Insulin damage DiaPep277 Anti-IL1 beta MMZ/Anti-IL2 DIABETES APDS Insulin Accept Damage Islet Cell Replacement Islet Cell Regeneration Reverse Damage
32 Nutrition Management Healthy Nutrition Carbohydrate Counting (helpful unless you forget about healthy nutrition) Glycemic Index (Individual foods)- compares the amount of insulin secreted in response to a food normalized to a fixed amount of carbohydrate Food Insulin Index (Combinations of foods) Bao et al, 2011, Diabetes Care 34:2146
33 Prevention of Complications Excellent A1c levels over time (DCCT, DPP, European Databases) Role of other CVD/PVD risk factors- ACE, statins, ASA, obesity prevention Nephropathy- Role of SphK1, fibronectin- Lan et al, 2011 Mol Endocrin 25:2094 Foot Ulcers- Maggot therapy- 5% of cost- Marineau, ICAAC 2011 Neuropathy- aldose reductase inhibitors (epralrestat approved in Japan)
34 Retinopathy Retinopathy- oral PK-C inhibitor (ruboxistaurin), TyrK inhibitor eye drops (pazopanib) in animal studies 53% reduction in retinopathy in teens over past 20 years- Downie et al, Diabetes Care 34: year incidence declined from 33% to 6 % with more recent diagnosis Prevalence not changed because people with complications live longer
35 Epidemiology SEARCH (< 21 yr olds: 1 in 500 have type 1, 1 in 4000 get it per year; 50% of the incident year olds get type 2) National Children s Study TEDDY Looking for infectious trigger for Type 1 Looking for supergenes for Type 2
36
Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationHow to Fight Diabetes and Win. Diabetes. Medications
How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationOral and Injectable Medication Options for Diabetes Treatment
Oral and Injectable Medication Options for Diabetes Treatment Presented by: Dr. Daphne E. Smith, Pharm.D., CDE Clinical Assistant Professor/Clinical Pharmacist-University of Illinois at Chicago College
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationDiabetes Basics. Type 1 diabetes The body cannot make insulin Requires insulin injection Is not treated with oral diabetes medicines (pills)
Diabetes Basics What is Diabetes? Diabetes is a disease in which the pancreas is unable to make insulin or the body is unable to use insulin or both. This leads to high blood sugar levels in the blood.
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More information1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime
Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationPharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN
Pharmacology Kacy Aderhold, MSN, APRN-CNS, CMSRN Biguanides Decreases hepatic glucose production and improves insulin sensitivity (increases number of insulin receptors) Common Adverse Reaction: diarrhea
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationDiabetes Medications: Oral Anti-Hyperglycemic Medications
Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationPhysician Drug Reference Chart for Diabetes Antidiabetic Medications
Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationRhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain
Rhonda Eustice, PharmD, CDE Will Power lasts about two weeks and is soluble in alcohol. Mark Twain Diabetes Management: The Three Legged Stool Diet Medication Exercise Objectives Know the treatment goals
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationDiabetes Treatment Guidelines
Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationImproving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes
Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Duality Statement Dr. Reid is a Speaker and Consultant
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationNon-Insulin Diabetes Medications Summary
Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationThe Community Pharmacist s Role in Diabetes Treatment
CONTINUING EDUCATION The Community Pharmacist s Role in Diabetes Treatment By Kimberly Ference, PharmD U pon completion of this activity, the pharmacist should be able to achieve these directives: 1. Describe
More informationDiabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016
Diabetes Mellitus Raja Nursing Instructor 09/03/2016 Acknowledgement: Badil Objective: Define Diabetes Mellitus (DM) & types of DM. Understand the pathophysiology of Type-I & II DM. List the clinical features
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationDIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0
Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol
More informationJeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October Your DM patient is ready for discharge, now what?
Jeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October 2018 Your DM patient is ready for discharge, now what? Financial Disclosures None Objectives 1. Understand follow up patterns/capability of patients
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationAACE/ACE Consensus Statement American Association of Clinical Endocrinologists and American College of Endocrinology
AACE/ACE Consensus Statement 2017 American Association of Clinical Endocrinologists and American College of Endocrinology Jeff Worrell, Lt Col, USAF (retired) CRNA MSN Why am I here? Metabolic Syndrome
More informationSHARP-SHOOTING MANAGING INSULIN LIKE A PRO
SHARP-SHOOTING MANAGING INSULIN LIKE A PRO Christine Kessler RN MN CNS ANP BC-ADM The Diabetes Institute Dept of Endocrinology & Metabolic Medicine Fort Belvoir Community Hospital, Fort Belvoir, VA Walter
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationPatient With Implantable Cardiac Device (ICD)
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER DALLAS Conundrums in Ambulatory Anesthesia II Girish P. Joshi, MBBS, MD, FFARCSI Professor of Anesthesiology and Pain Management Director of Perioperative
More informationPharmacy Drug Class Review
June 1, 010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Cardiovascular Impact of Diabetic Agents ACCORD, ADVANCE, VADT, UKPDS 10yr, PERISCOPE, PROactive Authored By: Lauren
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationThe information in this guide comes from a government-funded review of research about pills for type 2 diabetes.
effectivehealthcare.ahrq.gov Pills for Type 2 Diabetes: A Guide for Adults Consumer Summary Guide published 5 Dec 2007 1. Introduction What does this guide cover? Type 2 diabetes means the body has a problem
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationUnderstanding Diabetes and Insulin Delivery Systems
Page 1 This program has been supported by an educational grant from Sanofi Aventis Scott K. Stolte, Pharm.D. Associate Dean, Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University Winchester,
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationGlycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University
Glycemic Management of Type 2 Diabetes Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University 1 None Disclosures Learning Objectives Understand the
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More information3/16/2015. Improving the Management of Diabetes. W21 Angie Edmonds, PharmD, CGP Lorinda Babb, PharmD, CGP. Speaker Contact Information
Improving the Management of Diabetes W21 Angie Edmonds, PharmD, CGP Lorinda Babb, PharmD, CGP Speaker Contact Information Angie Edmonds Angela.edmonds@omnicare.com Lorinda Babb lorinda.babb@omnicare.com
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationNew Antidiabetic Medications
New Antidiabetic Medications A/Prof Harvey Newnham Director of General Medicine Clinical Program Director Emergency and Acute Medicine, Alfred Health, Melbourne 5 th May 2013 Diagnosed Diabetes USA Adults
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationClinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018
Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 RACHEL NAIDA, PHARMD, CDE CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF NEW ENGLAND COLLEGE OF PHARMACY
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationCURRENT STATEGIES IN DIABETES MELLITUS DIABETES. Recommendations for Adults CURRENT STRATEGIES IN DIABETES MELLITUS. Diabetes Mellitus: U.S.
CURRENT STATEGIES IN DIABETES MELLITUS Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Diabetes Mellitus: U.S. Impact ~1 Million Type 1 DIABETES 16.7 Million IFG (8.3%) 12.3
More informationWhat You Should Know About Diabetes. Laura Bingell RN Transition Center Nurse for MFP (607)
What You Should Know About Diabetes Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org Diabetes Mellitus (DM) a group of diseases marked by high blood glucose levels. 9.3%
More informationCE on SUNDAY Miami, FL May 31, 2009
CE on SUNDAY Miami, FL May 31, 2009 Date: Sunday, May 31, 2009 Time: 1:15 PM 2:15 PM Location: Doubletree Miami Mart/Airport Hotel Title: Speaker(s): Understanding Diabetes and Insulin Delivery Systems
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationDiabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System
Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationWhat is diabetes? DIABETES UPDATE Diabetes: An Epidemic. Cost of Care. Traditional Diagnosis: FBS 3/14/18. Diabetes: Magnitude of Complications
What is diabetes? DIABETES UPDATE 2018 Steven Ferrucci, OD, FAAO Chief, Optometry, Sepulveda VA Professor, SCCO/MBKU DM is a chronic disorder characterized by a lack of insulin or increased resistance
More informationDrug Therapy in Diabetes HEATHER TINGLE UK COLLEGE OF PHARMACY, PY4
Drug Therapy in Diabetes HEATHER TINGLE UK COLLEGE OF PHARMACY, PY4 OVERVIEW Characteristic Type 1 DM (10%) Type 2 DM (90%) Formerly known as Juvenile; Insulin-dependent Adult onset; Non-insulin dependent
More informationQuick Guide MEDICATIONS 7th Edition Evan Sisson, Pharm.D., MHA, CDE
Quick Guide to MEDICATIONS 7th Edition Evan Sisson, Pharm.D., MHA, CDE Adapted from The Art and Science of Diabetes Self-Management Education Desk Reference 2017, American Association of Diabetes Educators,
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationPreventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm
Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Algorithm Updated 9/13/2017 PHASE Populations DM: type 2 ASCVD: hx heart attack/cad, CVA, TIA, AAA, Sx PAD Lifestyle Modifications
More informationDiabetes Pharmacology
Diabetes Pharmacology PHPP 516 (IT-II) Spring 2016 JACOBS Wednesday, Jan 27 2:00 4:50 PM 1 Let s Learn about Diabetes 2 GLUCOSE UPTAKE Glucose FACILITATED DIFFUSION GLUT GK IMPERMEABLE GK = glucokinase
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationNew Medications and Prescribing Methods for Diabetic Patients
New Medications and Prescribing Methods for Diabetic Patients Jeffrey Stroup, PharmD, BCPS, FCCP Professor of Medicine Oklahoma State University Center for Health Sciences Department of Internal Medicine
More information